[
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting",
    "summary": "AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market volatility from tariff uncertainties that saw the Dow Jones drop over 900 points on certain days. As other sectors of the market faced declines, AbbVie's focus on new product...",
    "url": "https://finnhub.io/api/news?id=34d8f8572427b19d8bdc084fb1dea3b92d169294d7dbb66afa7a7fde3bbf28c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744047117,
      "headline": "AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting",
      "id": 133741116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market volatility from tariff uncertainties that saw the Dow Jones drop over 900 points on certain days. As other sectors of the market faced declines, AbbVie's focus on new product...",
      "url": "https://finnhub.io/api/news?id=34d8f8572427b19d8bdc084fb1dea3b92d169294d7dbb66afa7a7fde3bbf28c6"
    }
  },
  {
    "ts": null,
    "headline": "Syndax Pharmaceuticals: Down But Not Out",
    "summary": "Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.",
    "url": "https://finnhub.io/api/news?id=5e2e984882f8d5189cb1b46cec2720a49ca9e3e2cac1350b0e16fff99144f9f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744016920,
      "headline": "Syndax Pharmaceuticals: Down But Not Out",
      "id": 133738249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.",
      "url": "https://finnhub.io/api/news?id=5e2e984882f8d5189cb1b46cec2720a49ca9e3e2cac1350b0e16fff99144f9f8"
    }
  }
]